Brief: OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi

Ose Immunotherapeutics SA

25/01/2022 17:48

Jan 25 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS RECEIVES FIRST NOTICE OF ALLOWANCE
OF A
PATENT FOR USE OF TEDOPI® AFTER FAILURE WITH PD-1 OR PD-L1
IMMUNE CHECKPOINT INHIBITOR TREATMENT IN HLA-A2 POSITIVE CANCER
PATIENTS
    * ISSUED BY JAPANESE PATENT OFFICEA NEW PROTECTION COVERING
TEDOPI® UNTIL 2037
    * TODAY ANNOUNCED THAT JAPANESE PATENT OFFICE HAS ISSUED
NOTICE OF
ALLOWANCE FOR A NEW PATENT COVERING TEDOPI
    * PATENT, WHICH WILL FURTHER STRENGTHEN TEDOPI®'S GLOBAL
INTELLECTUAL PROPERTY PORTFOLIO IN IMMUNO-ONCOLOGY, WILL PROVIDE
PRODUCT WITH A NEW PROTECTION UNTIL 2037
    * NEW PATENT RECOGNISES INNOVATION OF A MULTIEPITOPE
COMPOSITION
(ALL PEPTIDES INCLUDED IN TEDOPI®) ADMINISTERED AFTER IMMUNE
CHECKPOINT INHIBITOR (PROGRESSION OF CANCER), IN PARTICULAR IN
SECONDARY RESISTANCE SITUATION

Source text for Eikon:  ID:nGNX3XDFbg 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))